CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $253.3 million in its third quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.18.
The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of $1.75 per share.
The RNA interference drug developer posted revenue of $125.9 million in the period, beating Street forecasts. Seven analysts surveyed by Zacks expected $117.5 million.
Alnylam shares have increased 21% since the beginning of the year. The stock has risen 52% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News